Syntara Limited (ASX:SNT) Filings

Syntara Limited

Filings

FilingDateTypeFiled with
Results of MeetingNov 18, 2026Meeting outcomeASX
CEO PresentationNov 18, 2026Other filingsASX
Chair's Address to ShareholdersNov 18, 2026Other filingsASX
Syntara Pauses SNT-9465 Phase 1b RecruitmentNov 9, 2026Operations updateASX
Quarterly Activities/Appendix 4C Cash Flow ReportOct 29, 2026Quarterly reportASX
Quarterly Activities/Appendix 4C Cash Flow ReportOct 29, 2026Quarterly reportASX
Notice of Annual General Meeting/Proxy FormOct 19, 2026Meeting noticeASX
Investor Presentation Canaccord Drug & Device ConferenceOct 12, 2026Other filingsASX
Further significant results from SNT-4728 iRBD Phase 2 trialOct 6, 2026Other filingsASX
Notification regarding unquoted securities - SNTOct 4, 2026Other filingsASX
Notification regarding unquoted securities - SNTOct 4, 2026Other filingsASX
Syntara expands SNT-9465 skin scarring studySep 30, 2026Operations updateASX
Syntara receives A$4.7m R&D Tax IncentiveSep 20, 2026Other filingsASX
Application for quotation of securities - SNTSep 14, 2026FinancingASX
Notification of 2026 AGM DateSep 14, 2026Meeting noticeASX
Appendix 4E and Annual ReportAug 27, 2026Annual reportASX
Appendix 4G and Corporate Governance StatementAug 27, 2026Other filingsASX
Investor Update Webinar PresentationJul 27, 2026Other filingsASX
Encouraging SNT-4728 Phase 2 iRBD resultsJul 5, 2026Other filingsASX
Results of Share Purchase PlanJun 10, 2026ResultsASX
Share Purchase Plan Offer BookletMay 13, 2026FinancingASX
$8m placement and share purchase planApr 29, 2026FinancingASX
Continuation of trading haltApr 28, 2026Trading halt or suspensionASX
Positive FDA feedback for Amsulostat P2b trialApr 27, 2026Operations updateASX
Half Year Report and Appendix 4DFeb 25, 2026Interim reportASX
Quarterly Activities/Appendix 4C Cash Flow ReportJan 28, 2026Quarterly reportASX
Amsulostat and Garvan in MRFF funded pancreatic trialJan 20, 2026Operations updateASX
SNT-4728 Phase 2 iRBD Parkinsons UK Trial fully recruitedJan 7, 2026Operations updateASX
Skin scarring program to progress on positive Phase1a resultNov 25, 2025Other filingsASX
Quarterly Shareholder Report and Appendix 4COct 27, 2025Quarterly reportASX
Positive top-line Phase 2a data confirms competitive profileSep 29, 2025ResultsASX
Preliminary Final ReportAug 28, 2025Annual reportASX
Guidance from FDA on amsulostat clinical progressionAug 11, 2025GuidanceASX
Reinstatement to QuotationAug 4, 2025Trading halt or suspensionASX
Suspension from QuotationJul 31, 2025Trading halt or suspensionASX
Quarterly Appendix 4C Cash Flow ReportJul 31, 2025Quarterly reportASX
Quarterly Shareholder ReportJul 30, 2025Quarterly reportASX
New positive interim data in Phase 2 study of SNT-5505Jun 12, 2025Other filingsASX
SNT-5505 awarded US FDA Fast Track designationJun 9, 2025Operations updateASX
Quarterly Activities ReportApr 29, 2025Quarterly reportASX
Acceleration of skin scarring programMar 17, 2025Other filingsASX
Equity Raising PresentationDec 11, 2024Other filingsASX
PlacementDec 11, 2024FinancingASX
Interim data in Phase 2 study of SNT-5505 in myelofibrosisDec 10, 2024Operations updateASX
Presentation: Phase 2 study of SNT-5505 in myelofibrosisDec 10, 2024Other filingsASX
Trading HaltDec 9, 2024Trading halt or suspensionASX
Response to ASX Price QueryDec 4, 2024Explanation requestASX
Pause in TradingDec 3, 2024Trading halt or suspensionASX
Appendix 4E and Annual Report to shareholdersAug 30, 2024Annual reportASX
Half Yearly Report and AccountsFeb 29, 2024Interim reportASX
PXS Company Restructure Sale of Mannitol BusinessOct 2, 2023Other filingsASX
PXS to Receive Prepayment of 2023 Research Tax IncentiveAug 7, 2023Other filingsASX
Final Set of Interim Data from PXS-5505 in MyelofibrosisJul 12, 2023Other filingsASX
PXS Announces Encouraging Results from Phase 1c Scar StudyMay 23, 2023Other filingsASX
After FDA Review PXS Accelerates Plans for Combination StudyApr 11, 2023Other filingsASX
PXS announces positive interim data from myelofibrosis trialOct 18, 2022Other filingsASX
Investor PresentationOct 18, 2022Other filingsASX
PXS Releases Promising Interim Data from Skin Scarring StudySep 25, 2022Other filingsASX
PXS to Receive Stg2.9m from Parkinsons UK for New TrialAug 31, 2022Other filingsASX
Aptar Pharma Pays PXS Us$5m to Acquire Orbital TechnologyAug 4, 2022Acquisition or disposalASX
Clarification AnnouncementMay 13, 2022Other filingsASX
Appendix 4C Quarterly Cash Flow ReportApr 28, 2022Quarterly reportASX
Response to ASX Aware QueryJan 10, 2022Explanation requestASX
PXS Collaborators Receive Government Grants of $1.4mJan 5, 2022Other filingsASX
Share Purchase PlanDec 20, 2021FinancingASX
Security Purchase PlanNov 24, 2021Other filingsASX
FDA Clears PXS Cancer Drug for Phase 2 Liver Cancer StudyNov 8, 2021Other filingsASX
Appendix 4C Cash Flow ReportOct 27, 2021Quarterly reportASX
PXS Doses First Patient in Phase 2 Bone Marrow Cancer TrialOct 13, 2021Other filingsASX
PXS Cleared to Progress to Phase 2 Bone Marrow Cancer TrialOct 4, 2021Other filingsASX
Pharmaxis Treatment to Prevent Wound and Burns Scars ClearsAug 30, 2021Other filingsASX
PXS Grants Exclusive Option to Develop High Payload InhalerAug 16, 2021Other filingsASX
PXS Drug Decreases Tumour Burden in Liver Cancer ModelAug 4, 2021Other filingsASX
PXS Sells Australian Distribution Rights for A$2mJun 30, 2021Other filingsASX
PXS Announces First Results in Bone Marrow Cancer TrialJun 29, 2021Other filingsASX
Quarterly Activity ReportApr 30, 2021Other filingsASX
Appendix 4C - quarterlyApr 30, 2021Quarterly reportASX
Sale of Russian Distribution RightsApr 13, 2021Other filingsASX
First Patient Enrolled - Clinical Trial for Cancer TreatmentFeb 21, 2021Other filingsASX
Pharmaxis Exports CF Drug to US - US$3 Million MilestoneFeb 8, 2021Other filingsASX
Quarterly Activity Report - December 2020Jan 28, 2021Other filingsASX
Pharmaxis Receives US$7m milestone from ChiesiDec 29, 2020Other filingsASX
Pharmaxis Prioritises Clinical Program on MyelofibrosisNov 1, 2020Other filingsASX
September Quarter 2020 Activity ReportOct 29, 2020Other filingsASX
Boehringer Ingelheim discontinues development of BI 1467335Sep 6, 2020Other filingsASX
Pharmaxis Awarded $1M Australian Government GrantSep 2, 2020Other filingsASX
FDA Gives Green Light to Start Myelofibrosis Phase 2 StudyAug 19, 2020Other filingsASX
US$7 million Bronchitol Launch Milestone Brought ForwardAug 4, 2020Other filingsASX
Fourth Quarter Activity ReportJul 30, 2020Other filingsASX
Pharmaxis Quarterly Shareholder Update - March 2020Apr 29, 2020Other filingsASX
PXS Cancer Drug Ready to Commence Phase 2 Studies Q4 2020Apr 27, 2020Other filingsASX
Quarterly Shareholder Update - December 2019Jan 30, 2020Other filingsASX
Pharmaxis Business Plan UpdateDec 17, 2019Other filingsASX
Quarterly Shareholder Update - September 2019Oct 30, 2019Other filingsASX
FDA Provides Guidance on Bronchitol Approval StepsOct 27, 2019GuidanceASX
Pharmaxis Receives $6.2m R&D Tax IncentiveOct 16, 2019Other filingsASX
Quarterly Shareholder Update - June 2019Jul 25, 2019Other filingsASX
Pathway to US Bronchitol Approval Clarified in FDA ResponseJun 19, 2019Other filingsASX
US Advisory Committee Positive Recommendation on BronchitolMay 8, 2019Other filingsASX
Quarterly Shareholder Update - March 2019Apr 29, 2019Other filingsASX
Pharmaxis Commences Phase 1 LOX Clinical TrialFeb 21, 2019Other filingsASX
Quarterly Shareholder Update - December 2018Jan 29, 2019Other filingsASX
Pharmaxis Announces LOXL2 Program Phase 2 ReadyJan 16, 2019Other filingsASX
PHARMAXIS ANNOUNCES RESUBMISSION OF BRONCHITOL NDA IN USADec 19, 2018Other filingsASX
Pharmaxis Announces First Relaunch Sales of Aridol in USADec 12, 2018Other filingsASX
Pharmaxis AGM - CEO PresentationNov 22, 2018Other filingsASX
LOX Inhibitor Program for Pancreatic Cancer Phase 1 ReadyNov 19, 2018Other filingsASX
Pharmaxis Releases Positive Results of Phase 1 Clinical TriaNov 14, 2018Other filingsASX
Positive Phase 1 Results of Phase 1 Study - LOXL2 InhibitorOct 10, 2018Other filingsASX
FDA Factory Approval and Relaunch of Aridol in US MarketAug 14, 2018Other filingsASX
Capital Raising PresentationAug 6, 2018FinancingASX
Trading Halt Announcement - System UpgradeAug 5, 2018Trading halt or suspensionASX
Quarterly Shareholder Update - June 2018Jul 26, 2018Other filingsASX
LOXL2 Program Attracts Strong Partner Interest at BIO18Jun 13, 2018Other filingsASX
Quarterly Shareholder Update - March 2018Apr 30, 2018Other filingsASX
Pharmaxis Earns A$15 Million Milestone PaymentJan 10, 2018Other filingsASX
New Australian PBS Listing for BrocnhitolJan 1, 2018Other filingsASX
Pharmaxis Acquires Control, Increases Stake in LOXL2 ProgramDec 13, 2017Acquisition or disposalASX
Boehringer Initiating Phase 2a Study Diabetic RetinopathySep 7, 2017Other filingsASX
Antifibrotic LOXL2 Program Clears Preclinical DevelopmentSep 5, 2017Other filingsASX
Boehringer Ingelheim Initiates Phase IIa Study in NASHAug 24, 2017Other filingsASX
Positive Recommendation for Broader Bronchitol Access in AusAug 18, 2017Other filingsASX
Preliminary Final Report June 2017Aug 10, 2017ResultsASX
Appendix 4C - quarterly June 2017Jul 28, 2017Quarterly reportASX
Pharmaxis Announces Results of Pivotal CF Clinical TrialJun 12, 2017Other filingsASX
Pharmaxis Set to Generate Further Euro 10m Milestone PaymentMay 14, 2017Other filingsASX
Pharmaxis Appoints Chiesi as Bronchitol Distributor in ItalyMay 8, 2017Other filingsASX
Appendix 4C - quarterly cash flowApr 18, 2017Quarterly reportASX
Quarterly Shareholder Update March 2017Apr 17, 2017Other filingsASX
Synairgen Collaboration ProgressMar 12, 2017Other filingsASX
Chairmans Address to ShareholdersNov 29, 2016Other filingsASX
Research Collaboration with Woolcock InstituteNov 15, 2016Other filingsASX
S&P DJ Indicies Announces March Quarterly RebalanceNov 7, 2016Other filingsASX
Pharmaxis Announces Russian Approval for BronchitolSep 26, 2016Other filingsASX
Pharmaxis Completes Recruitment of CF Clinical Trial for USJul 14, 2016Other filingsASX
Appendix 4C - quarterly March 2016Apr 14, 2016Quarterly reportASX
US FDA Accepts Bronchitol New Drug Application for ReviewMar 30, 2016Other filingsASX
Quarterly Share Update - December 2015Feb 11, 2016Other filingsASX
Bronchitol Paediatric CF Trial Reports Postive ResultsFeb 10, 2016Other filingsASX